Inspire Announces Resignation of Director.DURHAM, N.C. -- Inspire Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ISPH ISPH Inspire Pharmaceuticals, Inc. ) today announced that Gary D. Novack, Ph.D. has resigned, effective December 6, 2004, from the Board of Directors of Inspire Pharmaceuticals, Inc. to devote additional time to his growing consulting practice and his position as a Regent of the University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). . Inspire is currently seeking a replacement to fill Dr. Novack's vacated seat. "As an expert in the fields of ophthalmology ophthalmology (ŏf'thălmŏl`əjē), branch of medicine specializing in the anatomy, function and diseases of the eye. Ophthalmologists specialize in the medical and surgical treatment of eye disorders, vision measurements for and pharmacology, Gary has provided Inspire with a wealth of knowledge," stated W. Leigh Thompson, M.D., Ph.D., D.Sc., Chairman of the Board of Inspire. "However, the growth of Gary's consulting practice has now reached a point where he believes it is prudent to step down from the Board in order to focus his time and energy on his clients. We value Gary's integrity in making this decision and will miss his presence on the Board." Christy L. Shaffer, Ph.D., Chief Executive Officer of Inspire said, "We thank Gary for his dedicated service and contribution to Inspire. We appreciate Gary's valuable insight into our industry and we look forward to maintaining a relationship with him." Dr. Novack stated, "It has been a pleasure to work with the talented Board and management team at Inspire. This company is well-positioned for success and I look forward to working with Inspire in the future." About Inspire Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing novel prescription products for diseases with significant unmet medical needs. Inspire has significant technical and scientific expertise in the therapy areas of ophthalmology and respiratory and is a leader in the field of P2 receptors which are important drug targets in various therapeutic areas, including ophthalmology, respiratory disease Noun 1. respiratory disease - a disease affecting the respiratory system respiratory disorder, respiratory illness adult respiratory distress syndrome, ARDS, wet lung, white lung - acute lung injury characterized by coughing and rales; inflammation of the , cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease and pain. Inspire's specialty sales force promotes Elestat(TM) and Restasis(R), ophthalmology products developed by Inspire's partner, Allergan, Inc. Forward-Looking Statements The forward-looking statements in this news release relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc management's expectations and beliefs are based on preliminary information and management assumptions. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue and earnings expectations, intellectual property rights and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , competitive products, results of clinical trials, the need for additional research and testing, delays in manufacturing, funding and the timing and content of decisions made by regulatory authorities, including the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. . Further information regarding factors that could affect Inspire's results is included in Inspire's filings with the Securities and Exchange Commission. Inspire undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion